Browse studies

Find your next paid study

1,241 recruiting studies matching your filters

A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapse…

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT05091424

Observational

Collection of Uterine Lavage in High-Risk Patients as a Potential Biomarker for Ovarian Cancer Risk

This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BR…

BRCA Hereditary Ovarian CarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+1 more

Estimated

~$10 – $6,250

University of WashingtonNCT07772869

Phase 2

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy …

Foregut AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal Adenocarcinoma+6 more

Estimated

~$10 – $6,250

Yale UniversityNCT07282912

100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes

The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and …

AgingAging WellAll-Cause Mortality+12 more

Estimated

~$10 – $1,050

Longevity Metrics, Inc.NCT07563777

Phase 3

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ova…

Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213804

Phase 1

A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B203…

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT06427941

Phase 2

A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-sei…

SeizuresPrimary Motor CortexBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+2 more

Estimated

~$10 – $7,500

Ayal A. Aizer, MDNCT07130786

The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity

The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, dis…

AgingMortalityAll-cause Mortality+16 more

Estimated

~$10 – $1,050

Longevity Metrics, Inc.NCT07646782

Phase 2

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolli…

Advanced Solid TumorMelanomaHead and Neck Cancer+11 more

Estimated

~$10 – $7,500

Daiichi SankyoNCT06172478

Phase 3

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or c…

Non-Small Cell Lung CancerKRAS G12C Lung Cancer

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT06793215

Phase 1

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies…

Non-Small Cell Lung Cancer

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT05789082

Phase 3

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small …

Lung Non-Small Cell CarcinomaLung Non-Small Cell Squamous CarcinomaLung Non-Squamous Non-Small Cell Carcinoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04267848